No Data
No Data
Express News | Wedbush Reiterates Neutral on Alpine Immune Sciences, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone
Alpine Immune Sciences (ALPN) and Vertex Pharmaceuticals (VRTX) said Friday the waiting period under the Hart-Scott-Rodino antitrust act related to their merger deal expired Thursday. Vertex has agree
Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...
On May 9, 2024, Alpine Immune Sciences Inc (NASDAQ:ALPN), a prominent player in the field of immunotherapy for autoimmune and inflammatory diseases, disclosed its financial outcomes for the first quarter ending March 31, 2024.
RBC Capital Sticks to Its Hold Rating for Alpine Immune Sciences (ALPN)
Alpine Immune | 10-Q: Quarterly report